A novel two-dimensional nanocomposite Pt/Ti₃C₂T_x-CNT was synthesized for the non-invasive rapid detection of toluene, a lung cancer biomarker, via cataluminescence (CTL). Pt/Ti₃C₂T_x-CNT exhibited a good catalytic performance toward toluene. The CTL sensor based on Pt/Ti₃C₂T_x-CNT has the advantage of rapid response: The average response time was about 1 s, and the average recovery time was about 30 s. Moreover, the material has a wide scope of detection for toluene, and the limit of detection defined as 3 S/N was about 2 ppm. The optimal working temperature (150 °C) is lower than common sensors, so it has a broad prospect in the actual detection process. Aside from its weak response to formaldehyde, the sensor only exerted a strong response signal to toluene, and no response was observed to other VOCs, indicating that this CTL sensor has good selectivity for toluene. The possible sensing mechanism of CTL showed that toluene was oxidized to generate excited-state CO₂*, which emitted a luminescent signal when it returned to the ground state.

A double-aptamer sandwich strategy for dual-reporter SERS assay with reduced false-positive as practical protein testing tool in clinical diagnostics and prognosis.

A catalytic luminescence gas sensor based on flower shaped MoS ₂ is developed. The sensor has high sensitivity and good selectivity towards acetaldehyde.

Background: Immunotherapy combined with chemoradiotherapy has demonstrated promising efficacy in stage III non-small-cell lung cancer (NSCLC). However, the optimal timing for immunotherapy intervention during radiotherapy remains unclear. This study aimed to compare the efficacy and safety of immune checkpoint inhibitors (ICIs) administered concurrently or sequentially with chemoradiotherapy in unresectable stage III NSCLC.Methods: A retrospective analysis of 98 patients with unresectable stage III NSCLC, treated between January 1, 2019, and June 30, 2023, was conducted. Patients were grouped based on concurrent or sequential administration of ICIs with chemoradiotherapy. Median progression-free survival (mPFS), median overall survival (mOS), 1 and 2-year PFS rates, 2 and 3-year OS rates, objective remission rate (ORR), and disease control rate (DCR) were evaluated. Survival analysis was performed using the Kaplan–Meier method. Univariate and multivariate analyses were conducted using the log-rank test and Cox proportional hazards model. Treatment-related adverse effects were assessed and graded.Results: A total of 98 patients with unresectable stage III NSCLC treated with chemoradiotherapy and ICIs were included. The mPFS and mOS were 19.0 (14.2-23.8) months and 31.5 (24.3-38.7) months, 12.8 (9.5-16.1) months and 28.5 (19.3-37.7) months in the concurrent and sequential ICI groups, respectively, and mPFS showed a significant difference (P=0.047). The estimated 1 and 2-year PFS rates were 79.6% (95% confidence interval [CI]: 67.6-91.6) and 40.4% (95% CI: 15.8-49.2) for the concurrent group, compared to 51.0% (95% CI: 35.9-66.1) and 31.6% (95% CI: 14.5-48.7) for the sequential group. The estimated 2 and 3-year OS rates were 65.7% (95% confidence interval [CI]: 48.6-82.8) and 40.0% (95% CI: 16.1-63.9) for the concurrent group, compared to 54.6% (95% CI: 35.8-73.4) and 28.7% (95% CI: 4.8-52.6) for the sequential group. The Eastern Cooperative Oncology Group Performance Status Scale (ECOG) score and tumor differentiation were identified as independent factors associated with PFS and OS. Distant metastasis occurred in 13.8% and 25.5% of patients in the concurrent and sequential ICI groups, respectively (P=0.049). The incidence of any grade of pneumonitis was 43.1% and 38.3% in two groups, with grade 3 or higher in 7.8% and 8.5% of patients, respectively. Hematologic toxicity of any grade was observed in 29.4% and 34.0% of the two groups, with grade 3 or higher toxicity identified in 3.9% and 2.1% of patients, respectively.Conclusions: Concurrent immunotherapy combined with chemoradiotherapy demonstrated superior efficacy than sequential immunotherapy, with good safety and tolerability in patients with unresectable stage III NSCLC.

Since methanol has a significant health hazard due to its inherent toxicity, it is urgent to develop a method capable of rapid, sensitive, and continuous monitoring of methanol. The present study successfully synthesized a NiCo₂O₄/MIL-Ti₁₂₅ composite material and conducted a comprehensive analysis of its effectiveness for the detection of methanol employing cataluminescence (CTL) technology. The findings demonstrated that the composite material displays marked CTL in response to methanol, showcasing notable sensitivity, selectivity, and stability. The composite’s heterogeneous structure significantly improves the adsorption and reaction efficiency of methanol and further reduces the sensor’s working temperature. Under the optimal conditions of 215 °C and a flow rate of 300 mL/min, the CTL signal intensity is governed by the equation Y = 10.388X − 4.473 (R² = 0.982), with a detection limit as low as 0.431 ppm. The NiCo₂O₄/MIL-Ti₁₂₅ sensor exhibits high selectivity towards methanol. In addition, a relative standard deviation (RSD) of 4.95% demonstrates its excellent stability. Utilizing X-ray photoelectron spectroscopy (XPS), the study investigated the impact of elemental valence changes on the CTL process. We believe that the NiCo₂O₄/MIL-Ti₁₂₅ composite material, as a high-performance low-temperature CTL methanol sensor, is promising for applications.

A one-step, non-toxic, and direct method is developed to analyze the GNPs surface DNA number by iodide etching.